Table 1 Main characteristics of all the studies included in the meta-analysis
From: Meta-analysis of associations between neutrophil-to-lymphocyte ratio and prognosis of gastric cancer
First author | Publish time | Age (years) | Number of patients; stage of TNM | Treatment arm | NLR cutoff (HNLR/LNLR) | Follow-up (months) (median and range) | Study quality |
|---|---|---|---|---|---|---|---|
Lee S | 2013 | 55 ± 12.4a | 7/22/41/104; I to IV | Palliative/adjuvant chemotherapy | 3 (62/112) | 14.9 (1.0 to 47.9)b | 6 |
Lee DY | 2013 | 57 (23 to 89)b | 110/35/62/3; I to IV | Adjuvant chemotherapy | 2.15 (50/164) | NR | 5 |
Jin H | 2013 | 60 (37 to 77)b | 36/8; III to IV | Neoadjuvant chemotherapy | 2.5 (24/22) | NR | 5 |
Dirican A | 2013 | 58 (30 to 86)b | 6/20/105/105; I to IV | Palliative/adjuvant chemotherapy | 3.8 (89/147) | 60 | 5 |
Wang DS | 2012 | <65/230 ≥ 65/94 | 324; III | Adjuvant chemotherapy | 5 (156/168) | 39.9 (23.77 to 57.43)b | 6 |
Jeong JH | 2012 | 52.5 (28 to 82)b | 104; IV | Palliative chemotherapy | 3 (55/49) | 11.9 (10.2 to 13.5)b | 6 |
Mohri Y | 2010 | 63.4 (32 to 87)b | 232/57/68; I to III | Adjuvant chemotherapy/ neoadjuvant chemotherapy | 2.2 (130/227) | 68 (1 to 70)b | 5 |
Shimada H | 2010 | 65 (26 to 89)b | 584/132/153/159; I to IV | Adjuvant chemotherapy | 4 (127/901) | 23 (12 to 84)b | 5 |
Yamanaka T | 2007 | <60/493 ≥ 60/727 | 1220; IV | Palliative chemotherapy | 2.5 (664/576) | 15.6 | 6 |